A vaccine against Acquired immunodeficiency virus (HIV), has been successfully tested in mice by the AIDS vaccine research project Hivacat.

Christian Brander, scientific coordinator of the Hivacat project, explained in a press conference that they will proceed to test the effectiveness of this vaccine in rabbits and pigs, although the first phase of the study in humans will not be started until it has been proven that it is totally safe, for which They will need around two years.

The Hivacat, integrated by the Institute of AIDS Research IrsiCaixa and the Hospital Clínic of Barcelona, ​​in coordination with Laboratorios Esteve and with the support of the La Caixa Foundation and the Generalitat de Catalunya, after studies with a thousand patients, has managed to identify different fragments of proteins capable of stimulating the immune response.

One of the biggest difficulties when designing a vaccine against HIV lies in the great capacity of mutation of the virus

The advantage of this new vaccine is that it has been designed with the aim of stimulating immunity mechanisms, so that not only is it capable of generating protective antibodies against HIV, but it could also activate cells capable of destroying the virus.

Brander said that although the results are promising, there are still many obstacles to be overcome, since HIV presents an added difficulty, because it is a virus with an enormous capacity to mutate, since HIV mutates more than one virus person than all the flu strains worldwide.

For his part Julià Blanco, head of the Virology and Cellular Immunology group at IrsiCaixa, explained the enormous difficulty involved in designing a vaccine for AIDS, and recalled that inside a White blood cell There is room for up to one million HIV viruses, and the spread of the disease remains at the same levels as 30 years ago.


HIV today, gone tomorrow? (November 2019).